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Background: Aggregation of the α-Synuclein (α-Syn) protein, amyloid fibril formation and progressive
neurodegeneration are the neuropathological hallmarks of Parkinson's Disease (PD). However, a detailed
mechanism of α-Syn aggregation/fibrillogenesis and the exact nature of toxic oligomeric species produced during
amyloid formation process are still unknown.
Results: In this study, the rates of α-Syn aggregation were compared for the recombinant wild-type (WT) α-Syn and
a structurally relevant chimeric homologous protein containing an inducible Fv dimerizing domain (α-SynFv),
capable to form dimers in the presence of a divalent ligand (AP20187). In the presence of AP20187, we report a
rapid random coil into β-sheet conformational transformation of α-SynFv within 24 h, whereas WT α-Syn showed 24
h delay to achieve β-sheet structure after 48 h. Fluorescence ANS and ThT binding experiments demonstrate an
accelerated oligomer/amyloid formation of dimerized α-SynFv, compared to the slower oligomerization and
amyloidogenesis of WT α-Syn or α-SynFv without dimerizer AP20187. Both α-SynFv and α-Syn pre-fibrillar aggregates
internalized cells and induced neurotoxicity when injected into the hippocampus of wild-type mice. These
recombinant toxic aggregates further converted into non-toxic amyloids which were successfully amplified by
protein misfolding cyclic amplification method, providing the first evidence for the in vitro propagation of synthetic
α-Syn aggregates.
Conclusions: Together, we show that dimerization is important for α-Syn conformational transition and
aggregation. In addition, α-Syn dimerization can accelerate the formation of neurotoxic aggregates and amyloid
fibrils which can be amplified in vitro. A detailed characterization of the mechanism of α-Syn aggregation/
amyloidogenesis and toxicity is crucial to comprehend Parkinson's disease pathology at the molecular level.Background
Parkinson's Disease (PD) is an age-related deterioration
of dopaminergic neurons in the substantia nigra and
other brain regions. The pathological hallmark of PD is
the cytoplasmic deposition of amyloid-like aggregates
termed Lewy Bodies , the fibrous inclusions which con-
tain the protein α-Synuclein (α-Syn) [1-3]. α-Syn is a
soluble, natively unfolded protein containing 140 a.a.
which is expressed in the central nervous system includ-
ing the cerebral cortex, hippocampus, amygdala, and ol-
factory bulb [4,5]. Although it is known that α-Syn is
concentrated in presynaptic nerve terminals and appears
to be associated with vesicular structures, its exact bio-
logical function is still uncertain [6,7]. Overexpression of* Correspondence: xavier.roucou@usherbrooke.ca
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reproduction in any medium, provided the orthe wild-type α-Syn or mutant variants (A30P, A53T,
E46K) in several model organisms results in cytoplasmic
inclusion formation followed by neurodegeneration [8,9].
PD belongs to a larger category of neurodegenerative
diseases called protein misfolding disorders. The diag-
nostic feature common to protein misfolding disorders
involves the deposition of insoluble protein aggregates
and amyloid fibrils caused by accumulation of homolo-
gous proteins which are abnormally folded into β-sheet
structures [10,11]. There is growing evidence that
the pathogenic species causing cellular toxicity and
neurodegeneration are non-fibrillar dimers and oligomeric
assemblies [12-15]. Expression of α-Syn soluble oligomers
with reduced fibrillization propensity induced neurotox-
icity in worms, flies and mammalian neurons [16]. These
pre-fibrillar aggregate species are readily formed in vitro
from α-Syn mutants such as A30P and A53T, which areal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In Alzheimer’s disease and transmissible spongiform
encephalopathies, cytotoxicity of Amyloid-β oligomers
and prion protein, respectively, is significantly more
pronounced for rapidly formed pre-fibrillar aggregates
than for highly-organized amyloid structures [19,20]. The
exact biological function of amyloid inclusions is still
under debate. Recent experimental data indicate the cap-
acity of α-Syn amyloids to transfer between cells, both in
cultured cells and in transgenic mice [21]. Interaction of
α-Syn fibrils either with recombinant or cell-expressed α-
Syn converts soluble homologous proteins into a misfolded
state through a nucleation-dependent polymerization
process [22,23]. These results suggest that the mechanism
underlying propagation of α-Syn fibrils is reminiscent of
those by which tau aggregates and prions spread and trans-
mit the pathology through the brain tissue in Alzheimer’s
and prion diseases, respectively [24].
The molecular mechanism underlying α-Syn trans-
formation from its soluble monomeric form to the
disease-associated oligomeric conformation has been a
subject of intense research. Homodimer formation has
been characterized as an essential factor in the aggrega-
tion pathway of numerous proteins, such as serpin, tau,
and prion protein which are all involved in protein
misfolding disorders [14,25,26]. In this regard, in vitro
experiments have reported the existence of a dimeric
state during conversion of α-Syn from soluble
monomers to oligomeric species [27]. The dimerization
of α-Syn induced by intramolecular oxidative cross-
linking of tyrosine residues has been reported to induce
the aggregation process [28]. Substitution of cysteine for
tyrosine residues has been shown to induce α-Syn aggre-
gation and in vitro toxicity [29]. Interaction of α-Syn
with membrane phospholipids which results in the
formation of β-sheet dimers and oligomers is considered
to be a potential cytotoxic event, leading to the
permeabilization of the cell membrane [30]. However,
the importance of dimerization in α-Syn aggregation has
not yet been directly tested. In addition, it is not known
whether or not recombinant α-Syn dimers or oligomers,
which are highly potent to transform into amyloid fibrils,
are neurotoxic in vivo.
Here, we directly tested the hypothesis that dimerization
of α-Syn is a key molecular step in the aggregation of
α-Syn. We engineered a fusion protein between α-Syn and
an FK506 binding domain (Fv). In the presence of
AP20187, a divalent ligand that binds Fv, two protein
molecules containing an Fv module are forced to interact
and to dimerize. This strategy allows a fine regulation of
induced dimeric interactions between Fv-containing
proteins [14,31-34]. We demonstrate that dimerization is
the central mechanism of aggregation and fibrillogenesis
of α-Syn. Recombinant dimerization-induced oligomericspecies, but not structured insoluble amyloids, were
neurotoxic when injected to the brains of mice, consistent
with the toxicity of cell-expressed α-Syn mutants with the
propensity to form intermediate aggregates [16]. The
α-Syn oligomers proceeded to form stable amyloids which
could be amplified in vitro through the protein misfolding
cyclic amplification (PMCA) method [35]. These results
suggest that dimerization initiates α-Syn aggregation and
provide direct evidence for the in vivo toxicity of α-Syn
soluble prefibrillar aggregates.
Results
Dimerization accelerates α-Syn aggregation and
amyloidogenesis
Based on an inducible dimerizing system [14], we aimed
to characterize the role of dimerization in α-Syn aggre-
gation and fibrillogenesis. An Fv dimerizing domain was
fused to the C-terminal of α-Syn, thereby creating
α-SynFv with the capacity to homodimerize in the pres-
ence of AP20187. Analysis of the circular dichroism
spectrum of freshly purified recombinant α-SynFv or
α-Syn in the absence of AP20187 reveals a random coil
structure with minimum molar ellipticity at 198 nm
(Additional file 1: Figure S1, Figure 1A), consistent with
α-Syn native secondary structure [36]. Both α-SynFv and
α-Syn showed a conformational transition from random
coil to β-Sheet with a minimum at 216 nm within 48 h
(Figure 1A,B) [36]. However, in the presence of AP20187,
this transition was accelerated and occurred within 24 h.
The secondary structure transformation of α-Syn was
characterized by a negative peak with minimum ellipticity
at 208 nm after 24h incubation (Figure 1B), consistent
with recent demonstration of the existence of helical
intermediates during α-Syn aggregation [37].
Soluble recombinant α-Syn converts into aggregated
amyloids after 2–3 days of incubation with agitation at
37°C [36]; however, under static conditions, a prolonged
incubation time (> 30 days) is needed for α-Syn to as-
semble into amyloid fibrils [17]. Thus, we examined
whether induced α-Syn dimerization could increase
the rate of amyloidogenesis under static or dynamic
conditions. Electron micrographs of α-Syn preparations
showed amyloid fibril formation in both stationary and
agitating incubations with no detectable difference be-
tween the morphology of α-SynFv or α-Syn fibrils under
any experimental condition (Figure 2). Amyloid fibrils
were clearly detected after dimerization of α-SynFv
following 48 h of agitation or two weeks without agita-
tion. However, very few α-Syn fibrils were detected after
48 h of agitation, while under static conditions, α-Syn
required 3 weeks incubation to form detectable fibrils
(Figure 2). The kinetics of amyloid formation was then
monitored by Thioflavin T (ThT) fluorescence. ThT
exhibits a characteristic increase in fluorescence emission
Figure 1 Circular dichroic spectra of α-SynFv and α-Syn. (A) α-SynFv was incubated at different times in the absence (-AP20187) or in the
presence (+AP20187) of dimerizer at 37°C with agitation. (B) α-Syn was incubated different times as indicated in (A). Both α-SynFv and α-Syn
displayed structural transition from random coil to β-sheet conformation.
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the incubations including α-SynFv plus AP20187, max-
imum fluorescence intensity was observed within 30h.
Fibril quantification of α-Syn, in the presence or absence
of AP20187, showed a longer lag phase and highest ThT
emission achieved after 60h (Figure 3A). When 1% α-Syn
aggregates or α-SynFv dimerized aggregates were
incubated with soluble α-Syn and α-SynFv, respectively,
both proteins displayed the same capacity to trigger fibril
formation (Figure 3A). However, α-SynFv had a lower effi-
ciency to polymerize into fibrils in the absence of dimeriz-
ing conditions (Figure 3A). These results also exclude any
possibility that AP20187 or Fv domain could increase the
rate of fibril formation by α-Syn constructs.
Kinetics of early aggregation of α-Syn was determined
by the change in 8-anilino-1-naphthalenesulfonate
(ANS) fluorescence intensity, due to the presence of a
higher number of exposed hydrophobic sites, a key char-
acteristic of early aggregates and oligomeric intermediate
species [39]. ANS-binding experiments revealed the
rapid formation of α-SynFv pre-fibrillar aggregates within
2h of dimerization induced by AP20187, whereas assem-
bly of α-Syn monomers into oligomers was associated
with a significant (>2h) delay (Figure 3B).Accelerated formation of neurotoxic oligomers induced
by α-Syn dimerization
The demonstration that dimerized α-SynFv displayed a
higher capacity for ANS-binding over 24 h of aggrega-
tion compared to α-Syn (Figure 3B) suggested that
dimerization could accelerate the formation of toxic
oligomeric species [40]. To verify this hypothesis, neuro-
toxicity of aggregates and amyloid fibrils formed by
α-Syn or α-SynFv was determined by subcortical inocula-
tion of proteins into the right hippocampus of wild-type
C57BL/6 mice [41]. Indeed, hippocampal neurons are
highly susceptible to the neurodegeneration caused by
α-Syn aggregation [42].
The susceptibility of mice to α-Syn-induced neurotox-
icity was determined by monitoring hippocampal cells
for apoptosis 48 h post-injection by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay. Neuronal
cells were identified by immunofluorescence with an antibody
against the neuronal marker NeuN. Formation of toxic
aggregates was highly dependent on the oligomerization state
of α-Syn. Following agitating incubations, both dimerized
α-SynFv (Additional file 2: Figure S2) and α-Syn (Figure 4)
transformed into highly neurotoxic oligomers within 10 h and
24 h, respectively, and caused severe apoptosis in hippocampal
Figure 2 Electron micrographs of α-SynFv and α-Syn protein preparations. (A) α-Syn and α-SynFv were incubated at 37°C in different
conditions as indicated. (B) Freshly purified soluble α-Syn and α-SynFv observed by electron microscopy. Scale bar, 100 nm.
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tein toxic species were morphologically higher-ordered
aggregates of heterogeneous size, such as annular and
amorphous protofibrillar oligomers (Figure 4B, Additional
file 2: Figure S2B), with a high capacity to bind ANS
(Figure 3B). In contrast to the oligomers, neither soluble α-
Syn or α-SynFv proteins nor insoluble amyloid fibrils were
neurotoxic in our experiments (Figure 4A, Additional file 2:
Figure S2A, Additional file 3: Figure S3A). AlexaFluor 633-
labeled oligomers and amyloid fibrils were clearly visible in
the cytoplasm of neurons (Figure 4B, Additional file 2:
Figure S2C,D Additional file 3: Figure S3B). Therefore,
dimerization of α-Syn enhances the formation rate of toxic
oligomers which can further transform into insoluble amyl-
oid fibrils lacking neurotoxic activity.
In Vitro amplification of α-Syn fibrils
In PD pathology, topographical progression of α-Syn
aggregated amyloids or Lewy Bodies includes stereotypical
spread of Lewy Body formation from the lower brainstem
and anterior olfactory structures into the limbic system, neo-
cortex and other brain areas [43]. Recent data reported cell-
to-cell transmission of α-Syn aggregates both in cultured cells
and in transgenic mice [21]. These data strongly suggest thatα-Syn aggregates can polymerize by recruitment of soluble
homologous proteins and fragment to generate new seeds
which retain the capacity to nucleate newly synthesized sol-
uble monomers, thereby propagating protein aggregates
through the nervous system, in a mechanism similar to prion
propagation [23,44]. In order to determine if dimerized α-
SynFv aggregates could also display self-propagating activity,
we generated a modified in vitro conversion assay similar to
the PMCA protocol which has been used to convert cellular
prion protein into infectious prion aggregates [35]. Using this
assay we aimed to characterize the seeding effect of
dimerization on the initiation of propagation of α-SynFv
aggregates in the conditions relevant to the in vivo spread of
pathogenic form of α-Syn. Indeed, dimerization of α-Syn
might lead to a prion-like propagation which ultimately may
have implications for the spread of PD pathology in vivo. As
a positive control, we used wild-type α-Syn aggregates which
have been shown to be transmissible when injected to the
mouse brain [45]. Each cycle of PMCA was composed of
two phases (Figure 5A). During the first phase, α-Syn and α-
SynFv aggregates were diluted 20 times with soluble homolo-
gous protein and incubated 12 h with constant agitation to
induce the formation of amyloids. This dilution factor was
selected based on the observation that seeding with 5%
Figure 3 Biophysical characterization of the aggregation of α-Syn proteins monitored by ThT and ANS fluorescence.
(A) Amyloidogenesis of α-SynFv and α-Syn incubated at 37°C with agitation in different conditions was monitored with ThT over 80 h incubation
time. (B) Exposure of hydrophobic regions was monitored with ANS during 0–24 h incubation time.
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(Additional file 4: Figure S4A). Formation of large polymers
in the samples incubated for 12 h was determined by cen-
trifugation and SDS-PAGE analysis. The obtained results
confirmed that both α-Syn and α-SynFv were predomin-
antly insoluble at the end of a 12 h polymerization phase
(Additional file 4: Figure S4B). During the second phase
of PMCA, α-Syn and α-SynFv amyloids were sonicated in
order to fractionate fibril polymers and multiply seeds
for subsequent polymerization [46]. Centrifugation and
analysis of proteins in supernatant and pellet fractions
by SDS-PAGE confirmed the amplification of insoluble
aggregates by PMCA (Figure 5B). Densitometric ana-
lysis of the proteins in three independent experiments
definitively established that both α-Syn and α-SynFv
aggregates were efficiently amplified through PMCA using
our protocol (Additional file 5: Figure S5). High molecular
weight SDS-resistant species including dimers were formed
during the PMCA and could be detected by western blot
(Additional file 6: Figure S6A). The conversion of solubleα-Syn and α-SynFv into aggregated states and higher mo-
lecular weight species was observed through at least five
serial reactions (Figure 5B, Additional file 6: Figure S6A).
In a parallel experiment, samples were immediately centri-
fuged after 1/20 dilution of sonicated aggregates instead of
being submitted to a 12 h polymerization phase (Figure 5C).
No significant levels of insoluble proteins used to seed
the reaction were detected, indicating that insoluble
fractions detected after the PMCA cycles were essentially
formed from soluble monomers during the polymerization
phase. In control assays where proteins were subjected to
polymerization in a static phase for 12 h, no amplification
of protein aggregates was recorded, indicating the require-
ment of agitation for an efficient conversion (Figure 5D).
The dilution factor for the initial seeds used to start
PMCA was estimated to be 3.2 × 10-6 in the fifth cycle.
This concentration of seeds was insufficient to account for
the conversion of soluble proteins in PMCA cycles, dem-
onstrating that de novo generated α-Syn and α-SynFv
aggregates also gained their own seeding activity, as shown
Figure 4 In vivo neurotoxicity of synthetic α-Syn oligomers. (A) α-Syn protein was treated as indicated and injected into the brain of wild-
type C57BL/6 mice. Apoptotic neurons of the hippocampal region adjacent to the injection site were detected by TUNEL assay (green channel)
followed by confocal microscopy. Hippocampus in the injected hemisphere is shown in a dotted box. The neuronal marker NeuN is detected by
immunofluorescence (red channel). Nuclei are stained with Hoechst (blue channel). Scale bar, 500 μm. (B) Electron micrographs of toxic α-Syn
oligomers obtained after incubation at 37°C for 24 h. Scale bar, 25 nm. (C) Synthetic α-Syn aggregates were labeled with Alexa Fluor 633 prior to
injection and detected by confocal microscopy (aggregates, yellow channel; NeuN, red channel; nucleus, blue channel). Scale bar, 10 μm.
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In a control experiment, no formation of insoluble aggre-
gates was detected in the absence of added aggregates to
initiate the polymerization (Additional file 6: Figure S6B).
This result indicates that sonication and agitation do not in-
duce α-Syn aggregation in the absence of seeding aggregates.
Discussion
A detailed characterization of α-Syn aggregation and
amyloidogenesis is essential to comprehend the molecular
mechanisms of neurotoxicity and pathology spread in PD. A
critical challenge in understanding the mechanism of α-Syn
pathology, and in the subsequent design of intervention strat-
egies, has been the initiation of protein polymerization and the
correlation of aggregate formation with biological effects, such
as neurotoxicity and amyloid formation. In this study wedescribe the importance of dimerization in initiation and
acceleration of α-Syn aggregation and neurotoxicity. Under
physiological-like conditions, toxic aggregates can transform
into non-toxic amyloid fibrils which are amplified in vitro in
the presence of homologous soluble proteins, thereby generat-
ing de novo amyloids. The results discussed herein can open
new insights into the mechanism of α-Syn oligomerization
which is directly linked to the pathology of PD.
Importance of dimerization in formation of α-Syn toxic
aggregates and amyloid fibrils
Homodimerization of amyloid-forming proteins such as
prion protein, amyloid-β and serpin has been charac-
terized as a primary factor involved in aggregation and
pathogenesis of prion encephalopathies, Alzheimer’s dis-
ease and serpinopathies, respectively [14,26,47]. Here, we
Figure 5 PMCA reactions seeded with α-Syn or α-SynFv
aggregates. (A) Illustration of PMCA method used to amplify α-Syn or
α-SynFv aggregates in the presence of homologous soluble proteins
(see Materials and Methods). (B) α-Syn aggregates or α-SynFv
aggregates induced by AP20187 were diluted 20 times into freshly
prepared soluble proteins of the same species. Supernatant (S, soluble)
and pellet (P, insoluble) fractions recovered from centrifugation of 3 μg
protein samples withdrawn at the end of each PMCA cycle were
analyzed by SDS-PAGE and Coomassie blue staining. This result is
representative of three independent experiments. (C) α-Syn or α-SynFv
aggregates were diluted 1/20 into soluble homologous proteins and
immediately centrifuged. The absence of detectable protein in the
pellet fraction indicates the lack of amplification of aggregates.
(D) α-Syn or α-SynFv aggregates were submitted to two PMCA
cycles with incubations performed under stationary conditions.
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dimerization induces a conformational change to a β-
sheet rich structure (Figure 1). This results in a consider-
able increase in the rate of α-Syn aggregation and
amyloidogenesis (Figures 2 and 3A). In comparison to α-
Syn, accelerated aggregation of α-SynFv was associated
with the increased binding of ANS (Figure 3B), suggesting
that dimerization of α-Syn induced protein aggregation
through increase in surface hydrophobicity within the
amino acid side chains of aggregating proteins [40]. The
influence of hydrophobic interfacial area was recently
emphasized as a new factor for accelerating α-Syn aggre-
gation and amyloidogenesis [48]. In agreement with the
importance of dimerization for α-Syn aggregation andpathogenesis, another study has shown that dimeric
intermediates of WT and PD-associated mutants of α-
Syn were relevant species in protein aggregation and
cellular toxicity [49,50]. The increased aggregation rate
of dimerization-induced α-Syn may help misfolded proteins
to evade the cellular clearance machinery. In this scenario,
a feedback loop is generated through which α-Syn aggre-
gates impair the proteasome-mediated protein degradation
pathway [50], resulting in a further shift in the population
of α-Syn from soluble into cellular aggregates and amyloid
inclusions which are involved in PD pathogenesis.
Acceleration of protein aggregation and formation of
prefibrillar oligomers have been proposed to be associated
with PD-related neurotoxicity [16,18], however, there is a
lack of direct in vivo evidence on the neurotoxicity of α-
Syn oligomers and protofibrils. Previously, α-Syn oligomers
were shown to be toxic in rat brains, but animals were not
directly injected with recombinant oligomers; they were
infected with lentiviruses expressing α-syn mutants (E57K
and E35K) that favor oligomer assembly but lack the
amyloid forming capacity [51]. It should be noted that
α-Syn oligomerization is associated with amyloidogenesis
in most of the clinical cases of Parkinson's disease. In this
context, our results demonstrating that α-Syn oligomeric
species formed during the amyloidogenesis process are
neurotoxic species may be physiologically more relevant.
In addition, dimerization of α-Syn can significantly accel-
erate the formation of toxic oligomeric species and amyl-
oid fibrils with no toxic activity (Figure 4). Although toxic
protein aggregates contained spherical or amorphous
ultrastructures, the presence of smaller toxic species
undetectable by electron microscopy cannot be dis-
carded. Recent results on HypF-N, a bacterial protein
not associated with any amyloid disease, indicate that
hydrophobicity of oligomeric assemblies is a major de-
terminant of membrane interaction and cytotoxicity of
aggregate oligomers [40]. These observations are con-
sistent with the theory that hydrophobicity of protofibril
intermediates aids penetration of the membrane lipid
bilayer in order to form pore-like structures which dis-
rupt normal cellular physiology and cause neurotoxicity
[52]. Further research is required to evaluate this pro-
posal and other mechanistic issues concerning neuro-
toxicity, as well as the exact biological activity of α-Syn
aggregates.
PMCA of α-Syn aggregates
Emerging studies of protein misfolding disorders sug-
gest that the molecular mechanism underlying transmis-
sion of protein aggregation in Alzheimer’s, Huntington’s
and Parkinson’s diseases is similar to prion diseases
[11,45,53,54]. Recently, it was shown that a single
intrastriatal inoculation of synthetic α-Syn fibrils led to
the cell-to-cell transmission of pathologic α-Syn and
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regions [45]. Based on these evidences, we decided to
directly evaluate the in vivo theories on the propagation
of α-Syn aggregates and amyloid fibrils by developing a
modified PMCA assay (Figure 5A). In addition, we
investigated whether α-Syn amyloids seeded by
dimerization could initiate an in vitro cascade of nucle-
ation/polymerization through PMCA cycles. Our results
demonstrate that dimerization enhances the aggregation
of α-Syn, and fragmentation of α-Syn aggregates can
provide novel nucleation sites to induce conformational
conversion of newly added α-Syn soluble monomers
(Figure 5B). This in vitro propagation pattern of α-Syn
proposes that only the interaction between aggregates
and soluble α-Syn is sufficient to initiate amplification
of α-Syn aggregates. Formation of α-Syn aggregates has
been recently characterized in vivo in grafted human
fetal mesencephalic neurons implanted in the brain of a
patient with PD [53]. Therefore, our demonstration of
the in vitro replication of α-Syn amyloid aggregates in
the absence of cellular factors provides evidence for the
existence of a self-propagation system by which Lewy
Body formation eventually spreads throughout the ner-
vous system. Further research will have to determine
whether the PMCA intermediate products are neuro-
toxic and/or able to propagate after injection into the
brain of animal models by inducing the aggregation of
endogenously expressed α-Syn.
Could α-Syn dimers be a therapeutic target?
The phenomenon of protein dimerization has been
observed during aggregation and amyloidogenesis of α-
Syn. The A30P and A53T mutants, which are linked to
familial PD, display a faster rate of protein aggregation
and show a great propensity to self-interact and form di-
meric structures [17,28,49,50,55]. Here, we directly show
that α-Syn dimerization accelerates formation of neuro-
toxic intermediate aggregate species and amyloid fibrils
both of which are associated with PD pathology. Therefore,
compounds that prevent or slow down the dimerization
rate of α-Syn can block or hinder protein aggregation
which otherwise would be followed by a rapid accumula-
tion and deposition of neurotoxic oligomers and amyloid
inclusions. This information could be used to evaluate
transgenic animal models with accelerated PD pathology
caused by α-Syn dimerization. However, extensive research
is still required to indentify in vivo factors, such as uptake
or release of α-Syn by cells, involved in cell-to-cell transfer
of protein aggregates with seeding activity during pathology
spread throughout the nervous system [56].
Conclusions
By using a combination of in vitro and in vivo approaches,
we propose a mechanistic link between α-Syn dimerizationand aggregation with consequent neurotoxicity. Indeed, this
study provides direct evidence on the impact of dimer-
ization on the α-Syn oligomerization and amyloidogenesis
rates. Acceleration of oligomerization can subsequently
induce the formation of neurotoxic aggregates and
amyloid fibrils which can be propagated in vitro in a
prion-like manner. The important finding that both α-
Syn and α-SynFv synthetic aggregates can induce neuro-
toxicity confirms the literature data and provides new
experimental tools for studying a direct cause and effect
relationship between the aggregation of α-Syn and forma-
tion of neurotoxic species. Finding the precise correlation
between different oligomeric structures and neurotoxicity
in PD pathogenesis is essential to comprehend the
molecular mechanism of pathology. In this context,
characterization of the globular aggregates as neurotoxic
species is an important step toward understanding the path-
ology of PD at the molecular level.
Methods
Cloning of α-Syn constructs
Total RNA was extracted from HeLa cells using the Trizol
reagent (Invitrogen), according to manufacturer's
instructions. α-Syn and α-Syn-Fv constructs were
generated using PCR primers listed in Additional file 7:
Table S1. α-Syn cDNA was produced using α-Syn-Fw and
α-Syn-Rv PCR primers specific to the 3’ and 5’ untrans-
lated region of α-Syn mRNA. The full-length C-terminally
6xHis-tagged recombinant α-Syn was amplified from
α-Syn cDNA using the α-Syn-His-Fw and α-Syn-His-Rv
primer pair. α-Syn cDNA was also used as a template to
produce 6xHis-tagged recombinant α-SynFv by overlap
extension PCR, using α-SynFv-Rv, α-SynFv-Fw and
Fv-His-Rv primers. Fv was amplified from pC4-Fv1E
(Invitrogen). To avoid cysteine misincorporation at codon
136 in bacterially expressed α-Syn constructs and artefac-
tual autodimerization [57], site-directed mutagenesis
of codon 136 (Y136-TAC to Y136-TAT) was done
using α-Syn-FwY136-TAT/ α-Syn-RvY136-TAT and α-Syn-Fv-
FwY136-TAT/α-Syn-Fv-RvY136-TAT primer pairs to generate
α-Syn and α-SynFv final constructs, respectively. PCR
amplification fidelity was confirmed by sequencing and
constructs were inserted into PET-21b vectors using NdeI
and HindIII cloning sites.
Expression and purification of α-Syn and α-SynFv
Constructs were overexpressed in BL21(DE3)pLysS cells
at 25°C with slow shaking, using 0.1 mM IPTG (isopro-
pyl β-D-thiogalactoside) for 10 h. The bacterial pellets
were lysed in 300 mM NaCl, 50 mM NaH2PO4 (pH 8.0),
1 mM PMSF, 0.1 mM TCEP [tris-(2-carboxyethyl)
phosphine] and 1 mg/ml lysozyme, followed by either
drawing–expelling of the lysates through a 21-gauge
-needle or a brief sonication followed by centrifugation
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supernatant was carried out using nickel-affinity chro-
matography according to the manufacturer's protocol
(Qiagen). Proteins were eluted in a buffer consisting of
125 mM NaCl, 300 mM imidazole, 0.1 mM TCEP, 25
mM NaH2PO4 (pH 7.4). This buffer was then exchanged
for a physiological buffer [58] consisting of 50 mM
K3PO4, 2 mM KCl, 70 mM CH3COOH, 9 mM KH3PO4
and 5 mM Na2HPO4 (pH 7.4), using Millipore ultracen-
trifugation filters (Amicon Canada). The concentration
of proteins was estimated by the absorbance at 280 nm,
considering molar absorption coefficients of 15392
M−1·cm−1 and 28660 M−1·cm−1 for 6xHis-tagged α-Syn
and α-SynFv, respectively. The recombinant proteins
were detected by SDS-PAGE and western blot using
monoclonal antibody (EP1646Y) to α-Syn.
Amyloid assembly experiments
α-SynFv (5.7 mg/ml) and α-Syn (3.0 mg/ml) in the pres-
ence or absence of 10 μM AP20187 (divalent ligand) or
10 μM FK506 (monovalent ligand) were used in the
amyloid assembly preparations. Samples were incubated
in 0,5 ml physiological buffer supplemented with 0,02%
NaN3 (pH 7.4) in microtubes with or without agitation
at 300 rpm at 37°C. Aliquots were withdrawn at different
time intervals from samples incubated in agitation or
static conditions, and were analyzed by biochemical and
biophysical methods (see below).
Circular dichroism spectroscopy
Circular dichroism measurements were done as described
before [59]. α-SynFv and α-Syn were taken from amyloid
assembly incubations and diluted to 20 μM in phosphate
buffer (25 μM Na2HPO4). Samples were transferred into
0.1 cm light-path quartz cuvettes and far UV spectra
(190–250 nm) were recorded on a Jasco J-810 CD spec-
trophotometer at 25°C. Three consecutive scans were
accumulated and the average spectra were recorded. Raw
data were converted to molar ellipticity and plotted as a
function of wavelength.
Thioflavin T and 8-anilino-1-naphthalenesulfonate binding
Thioflavin T binding to α-Syn and α-Syn-Fv amyloid
samples withdrawn from amyloid assembly experiments
at the indicated time points was evaluated as described
before. Binding of 8-anilino-1-naphthalenesulfonate to
α-Syn and α-SynFv was evaluated by measuring the fluor-
escence enhancement of 8-anilino-1-naphthalenesulfonate
(50 μM) in the presence of 85 μM protein preparation
upon excitation at a wavelength of 380 nm. The emission
spectra were integrated from 400 to 600 nm. Values are
expressed as the mean ± S.E.M. of maximum fluorescence
intensity from three independent experiments.Electron microscopy
A 10 μL sample from amyloid assembly preparations
was taken for EM analysis. Samples included α-SynFv or
α-Syn amyloids after 10 h, 24 h and 48 h agitation at
37°C. Aliquots were also withdrawn after 1, 2 and 3
weeks from stationary incubations. Protein samples were
applied to formar- and carbon-coated grids. The excess
fluid was drained with filter paper and the samples were
stained for 1 min with 2% uranyl acetate. The grid was
air-dried and examined in a Hitachi H-2500 electron
microscope at 80 kV at a magnification of 15–75000.
In vivo neurotoxicity experiments
Inocula were protein aliquots prepared with sterile
solutions withdrawn from amyloid assembly experiments
after 10 h, 24 h, and 48 h shaking at 37°C. One month
old male WT C57BL/6 mice were anesthesized with
ketamine/xylazine (1ml/kg, 87/13) and positioned on a
stereotaxic frame. Coordinates for the injection site were
1.50 mm posterior and 1.75 mm ventral to the bregma
and 2.00 mm lateral to the midline. 2 μl physiological
buffer or 2 μl protein samples (40 μM) were injected at
a rate of 0.4 μl/min. After 48 h, mice were anesthetized
using isoflurane followed by euthanasia by cervical dis-
location, according to the Animal Ethics Committee of
the Université de Sherbrooke. A group of 18 mice was
injected. Each of the three protein preparations (protein
aliquots withdrawn from amyloid assembly experiments
after 10 h, 24 h, and 48 h shaking at 37°C for α-SynFv;
and protein aliquots withdrawn from amyloid assembly
experiments after 24 h, 48 h, and 72 h shaking at 37°C
for α-Syn) was injected in three mice. Two independent
experiments were performed, with a total of 36 mice.
Detection of apoptotic cells
To detect apoptotic cells, brain sections adjacent to the
injection site were tested by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay using
Dead End Fluorometric TUNEL System (Promega),
according to the manufacturer’s protocol. Nuclei were also
stained with Hoechst. For confocal analysis, brain sections
were examined with a scanning confocal microscope
(FV1000, Olympus, Tokyo, Japan) coupled to an inverted
microscope with a 63X oil immersion objective (Olym-
pus). Specimens were laser-excited at 488 nm (TUNEL-
positive signals) and 405 nm (Hoechst). In order to avoid
cross-talk between the fluorescence emitted by Hoechst
(405) and Alexa 488, images were acquired sequentially.
Serial horizontal optical sections of 320 X 320 pixels were
taken at 1.0 μm intervals through the entire thickness of
the tissue (optical resolution: lateral 0.18 μm; axial 0.25
μm). Identical settings of the instrument were used for
all photos. For illustration purposes, images were
pseudocolored according to their original fluorochromes,
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assembled (Adobe Photoshop software, Adobe Systems,
Mountain View, CA).
Detection of recombinant α-syn species in neuronal cells
Protein preparations were labeled with Alexa Fluor 633
a protein labeling kit as described by the manufacturer
(Molecular Probes, A20170). The Alexa 633-labeled in-
ocula were injected in the mice brain as described.
Brain nuclei were stained with Hoechst and neuronal
cells were identified by immunofluorescence using
NeuN antibody. Brain sections were examined with a
scanning confocal microscope with a 60X oil immersion
objective (Olympus). Specimens were laser-excited at
633 nm to detect Alexa-labeled α-syn and α-SynFv
preparations, 568 nm (NeuN) and 405 nm (Hoechst). In
order to avoid cross-talk between the fluorescence emitted
by different dyes, images were acquired sequentially. Serial
horizontal optical sections of 320 X 320 pixels were taken
from CA2-CA3 hyppocampal neurons and focal planes
were stacked for optimal α-syn detection. Identical
settings of the instrument were used for all photos. For
illustration purposes, each dye was pseudocolored
(FluoView software, Olympus).
Protein misfolding cyclic amplification (PMCA) of α-Syn
PMCA reactions were prepared in 1.7 ml ultraclear
microtubes as 300 μl solutions containing physiological
buffer (pH 7.4). In the first cycle, 22.5 μl aliquots from
48 h fibril assembly experiments of α-SynFv or α-Syn
were added to 300 μM soluble α-SynFv and α-Syn in
physiological buffer solutions, respectively, to give a
fibril/protein ratio of 1:20. In the elongation step,
reactions were initiated by incubating samples at 37°C
with shaking (300 rpm) for 1 h during which 6X periodic
sonication/incubation cycles (30s sonication followed by
10 min shaking) were performed to prepare homoge-
neous aggregate seeds. This step was followed by incuba-
tion of samples for 10 h with constant shaking (37°C) to
elongate amyloid fibrils. After 10 h incubation, newly
formed amyloids were subjected to periodic sonication/
incubation cycles for 1 h (as described above) to frac-
tionate amyloid fibrils in order to provide a solution of
amyloid seeds. Fractionated amyloids were then diluted
1/20 in physiological buffer containing 300 μM soluble
proteins and identical elongation and fractionation
cycles were applied to complete the PMCA round. These
cycles were consecutively repeated at least five times and
at the end of each PMCA round, 50 μl aliquots were
withdrawn centrifuged at 20 000 g for 1 h to separate in-
soluble amyloids from the supernatant. Proteins from
the supernatant fractions were precipitated with four
volumes of methanol. 2 μg of protein from each pellet or
supernatant were subjected to SDS-PAGE analysis andCoomassie blue staining and band densities were
analyzed with AlphaEaseFC software (Alpha Innotech).
To verify the importance of shaking in the efficiency of
PMCA, control cycles were performed in static
conditions. To confirm the importance of elongation,
after 1/20 dilution of amyloid seeds, samples were spun
as described and both soluble and insoluble fractions
were stored at −20°C until SDS-PAGE analysis.Additional files
Additional file 1: Figure S1. Expression and purification of α-Syn and
α-SynFv. Recombinant proteins were produced in BL21(DE3)pLysS
Escherichia coli cells, as described under “Materials and Methods”. 2 μg of
recombinant proteins was subjected to the SDS-PAGE and Coomassie
blue staining (left panel). Purity of the proteins was estimated to be
superior to 95%. Identity of the proteins was confirmed by
immunoblotting using monoclonal anti-α-Syn EP1646Y antibody (right
panel).
Additional file 2: Figure S2. In vivo neurotoxicity of synthetic α-SynFv
oligomers. (A) α-SynFv protein was treated in the absence (soluble) or in
the presence of 10 μM AP20187 (aggregates and amyloids) as indicated,
and injected into the brain of wild-type C57BL/6 mice. Apoptotic
neurons of the hippocampal region adjacent to the injection site were
detected by TUNEL assay (green channel) followed by confocal
microscopy. Hippocampus in the injected hemisphere is shown in a
dotted box. The neuronal marker NeuN is detected by
immunofluorescence (red channel). Nuclei are stained with Hoechst (blue
channel). Scale bar, 500 μm. (B) Electron micrographs of toxic α-SynFv
oligomers obtained after incubation at 37 ºC for 10 h. Scale bar, 25 nm.
(C) Synthetic α-SynFv aggregates were labeled with Alexa Fluor 633 and
detected by confocal microscopy (aggregates, yellow channel; NeuN, red
channel; Nucleus, Blue channel). Scale bar, 10 μm. (D) Synthetic α-SynFv
amyloids were labeled with Alexa Fluor 633 and detected by confocal
microscopy (aggregates, yellow channel; NeuN, red channel; nucleus,
blue channel). Scale bar, 10 μm.
Additional file 3: Figure S3. Absence of in vivo neurotoxicity of
synthetic α-Syn amyloids. (A) α-Syn protein was treated as indicated, and
injected into the brain of wild-type C57BL/6 mice. Apoptotic neurons of
the hippocampal region adjacent to the injection site were detected by
TUNEL assay (green channel) followed by confocal microscopy.
Hippocampus in the injected hemisphere is shown in a dashed box. The
neuronal marker NeuN is detected by immunofluorescence (red channel).
Nuclei are stained with Hoechst (blue channel). Scale bar, 500 μm. (B)
Synthetic α-Syn amyloids were labeled with Alexa Fluor 633 and
detected by confocal microscopy (aggregates, yellow channel; NeuN, red
channel; nucleus, blue channel). Scale bar, 10 μm.
Additional file 4: Figure S4. Acceleration of α-Syn amyloid formation
in seeding incubations. (A) 200 μM of freshly prepared recombinant α-
Syn or α-SynFv was incubated with 2% or 5% homologous amyloid seeds
with agitation at 37°C for 80 h. α-SynFv seeds were produced in the
presence of AP20187. α-Syn seeds were obtained by agitating α-Syn for
48 h at 37ºC. (B) Aliquots withdrawn at 4 h intervals from the incubations
including 5% seed were analyzed by centrifugation, SDS-PAGE and
Coomassie blue staining.
Additional file 5: Figure S5. Densitometric analysis of PMCA reactions
with α-Syn and α-SynFv in three independent experiments. α-Syn
aggregates or α-SynFv aggregates induced by AP20187 were diluted 20
times into freshly prepared soluble proteins of the same species.
Supernatant (S, soluble) and pellet (P, insoluble) fractions recovered from
centrifugation of 3 μg protein samples withdrawn at the end of each
PMCA cycle were analyzed by SDS-PAGE and Coomassie blue staining.
Additional file 6: Figure S6. Analyses of PMCA reactions. (A) SDS-
resistant α-Syn and α-SynFv species after PMCA in pellet fractions. At the
Roostaee et al. Molecular Neurodegeneration 2013, 8:5 Page 11 of 12
http://www.molecularneurodegeneration.com/content/8/1/5end of each PMCA cycles using purified recombinant proteins (Figure 5),
proteins in the pellet were analyzed by western blot using monoclonal
anti-α-Syn EP1646Y antibody. (B) Control experiments in the absence of
seeds. The PMCA reaction was not seeded with α-SynFv aggregates. At
the end of each PMCA cycle, proteins in the pellet were analyzed by
western blot using monoclonal anti-α-Syn EP1646Y antibody.
Additional file 7: Table S1. Oligonucleotides used to produce α α-Syn
constructs.
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